Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.39 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966539 | 0.87 | ALDH1A1 (0.55) | KDM4EUSP2ALDH1A1MEN1HSP90AA1 | |
| SCHEMBL23914639 | 0.82 | ALDH1A1 (0.37) | ALDH1A1MAPTAAK1MBOAT4QPCT | |
| SCHEMBL23915464 | 0.78 | ALDH1A1 (0.44) | KDM4EUSP2ALDH1A1MEN1MAPT | |
| SCHEMBL23862114 | 0.77 | AAK1 (0.37) | AAK1MBOAT4ARQPCT | |
| SCHEMBL16071292 | 0.75 | AAK1 (0.53) | AAK1ARQPCT | |
| SCHEMBL23915318 | 0.75 | ALDH1A1 (0.43) | KDM4EUSP2ALDH1A1MEN1HSP90AA1 | |
| SCHEMBL22900437 | 0.74 | AAK1 (0.39) | AAK1MBOAT4ARQPCT | |
| SCHEMBL23909016 | 0.73 | MBOAT4 (0.36) | KDM4EUSP2ALDH1A1AAK1MBOAT4 | |
| SCHEMBL23914846 | 0.73 | AR (0.45) | KDM4EUSP2ALDH1A1AR | |
| SCHEMBL16071293 | 0.72 | AAK1 (0.38) | AAK1ARQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | KDM4E 3835/4885USP2 4521/4885ALDH1A1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.